Other languages Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
24.13 ^USD	+6.53%		+4.14%	+136.80%

May. 15	Cullinan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 15	Cullinan Therapeutics, Inc. Announces Board Changes	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cullinan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
Cullinan Therapeutics, Inc. Announces Board Changes	May. 15
Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing	May. 09
Cullinan Therapeutics Appoints Mary Kay Fenton as CFO	Apr. 29
Cullinan Oncology, Inc. Announces Important Updates About Its Plan to Expand into Autoimmune Diseases, the Scientific Rationale for Developing CLN-978 in Autoimmune Diseases	Apr. 16
Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave	Mar. 14
Cullinan Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14
Cullinan Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14
Cullinan Oncology Secures FDA Approval for CLN-619's Investigational New Drug Application in Multiple Myeloma	Mar. 01
Cullinan Oncology Insider Sold Shares Worth $647,200, According to a Recent SEC Filing	Feb. 05
Cullinan Oncology Insider Sold Shares Worth $563,600, According to a Recent SEC Filing	Jan. 31
Cullinan Oncology Doses First Patient in Study of Advanced Solid Tumor Treatment Candidate	Dec. 15
Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines	Dec. 14
Cullinan Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023	Nov. 03
Cullinan Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 Trial	23-08-03
Cullinan Oncology, Inc. Announces Transition of Patrick Baeuerle from Chief Scientific Officer of the Company to Co-Founder, Chief Scientific Advisor, Chair of Scientific Advisory Board	23-06-14
Insider Sell: Cullinan Oncology	23-06-08
Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid Tumors	23-05-25

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Other languages

Filters